Another famous pharmaceutical company was acquired! Acquisition and transfer or become normal in the pharmaceutical industry?

[industry trends of pharmaceutical network] on November 30, Nanjing Pharmaceutical Co., Ltd issued the announcement on the acquisition of 70% equity of Jiangsu Enhua Herun Pharmaceutical Co., Ltd According to the announcement, after the completion of the equity transaction, Nanjing Pharmaceutical will directly hold 70% of the equity of Enhua and run, with a total purchase price of 72.24 million yuan Nanjing Pharmaceutical said that the acquisition is to further focus on the company's main business development, improve the overall business network construction in Jiangsu, and improve the market coverage capacity of Xuzhou and Huaihai economic zone It is reported that Nanjing Pharmaceutical Co., Ltd., founded in 1951 and listed on the Shanghai Stock Exchange in 1996, is the first listed company in domestic pharmaceutical circulation In recent years, as a state-owned holding enterprise, Nanjing Pharmaceutical has always adhered to scientific development and harmonious development, gradually growing from a regional single enterprise to a large enterprise with nearly 8000 employees, more than 50 subsidiaries and annual sales of more than 10 billion yuan According to its 2018 annual report, its realized income is RMB 31.303 billion, up 8.65% year-on-year; net profit attributable to the parent is RMB 264 million, up 13.70% year-on-year; net profit attributable to the parent after deduction is RMB 244 million, up 17.87% year-on-year In 2018, it also completed the equity acquisition of Nanjing Huadong pharmaceutical and Nanjing Jinling pharmacy, further integrating pharmaceutical wholesale and retail resources In addition, taking Nanjing Pharmaceutical headquarters as the provincial platform, aiming at the original blank area, new branch companies have been established in Changzhou, Taizhou, Suzhou, Lianyungang and Zhenjiang areas of Jiangsu Province to further develop the regional market, and the regional market coverage has been effectively improved In 2018, a total of 6055 effective customers have been added to medical institutions and retail terminals, a year-on-year increase of 29.34% The continuous promotion of new business and new mode, such as the pilot project of PBM chronic disease management project through Nanjing Medical Reform benchmark hospital, also provides new opportunities and growth points for its rapid development At present, Enhua Herun is a subsidiary of Enhua pharmaceutical, a listed company Its business includes pure sales, retail, instant sales and commercial distribution of drug hospitals, with more than 12000 drug and medical devices available, covering six counties in one city of Xuzhou, parts of Central Jiangsu and southern Jiangsu, and the border area between Anhui and Xuzhou At present, it ranks the third in pharmaceutical business in Xuzhou and is one of the top 100 pharmaceutical business enterprises in China For the acquisition of 70% equity of the holding subsidiary, Jiangsu Enhua pharmaceutical said that this is to further focus on the development of its main business, concentrate resources on research and development of central nervous products, and constantly improve its core competitiveness In fact, in recent years, the acquisition and transfer of part of the equity in the pharmaceutical industry are endless For example, Lingkang pharmaceutical, a listed company, announced earlier that it would purchase 25% of Chengmei International's shares held by Hainan Cancer Hospital Co., Ltd for 100 million yuan in cash It said the acquisition will expand the company's business type and is the company's first attempt to enter the field of high-end medical services On May 26, Huadong pharmaceutical announced that it planned to acquire 18.60% shares of zoelli pharmaceutical with no more than 1.06 billion yuan to realize holding Zoelli pharmaceutical focuses on the R & D, production and sales of medicinal fungi series products, Chinese herbal pieces and Chinese herbal formula particles And said that the acquisition is expected to enrich the number of products in the direction of chronic diseases of traditional Chinese medicine and the coverage of indications, give full play to the company's advantages in the grass-roots market network, and further expand and strengthen the characteristic drugs of chronic diseases of traditional Chinese medicine Recently, Tonghua Jinma also announced that it plans to purchase the equity of Jikuang hospital and shuangkuang hospital held by Dexin Yili and shengzezhou respectively by means of cash payment, with a preliminary transaction consideration of 1.53 billion yuan After the completion of the transaction, Tonghua Jinma respectively holds 85% shares in Jikuang hospital and shuangkuang hospital At present, it seems that whether acquisition or transfer is for the purpose of in-depth layout of enterprises' main business and other development strategic needs In the future, the acquisition and transfer between enterprises may become the normal in the pharmaceutical industry.